EGFR exon 20 insertion lung cancer briefly had two targeted options approved within months of each other. Exkivity (mobocertinib) was the oral one, and it did not last.
Designed to bind the altered EGFR conformation these insertions produce, the once-daily oral inhibitor held accelerated approval for locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations after platinum-based chemotherapy.
Takeda voluntarily withdrew Exkivity from the U.S. market in 2023 after the confirmatory EXCLAIM-2 trial failed to show a progression-free survival benefit over platinum chemotherapy. Its withdrawal left Rybrevant as the principal targeted option in the indication.
